Continuous Glucose Monitoring Metrics and Risks of Severe Hypoglycemia and Diabetic Ketoacidosis in Type 1 Diabetes: A Pooled Analysis
Diabetes Care · 2026
DOI: 10.2337/dc26-1042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, 2026. Verfasst von Jiahuan Helen He und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetic Ketoacidosis, Hypoglycemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, Division of Diabetes, Endocrinology, and Metabolic Diseases.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE To investigate the link between continuous glucose monitoring (CGM) metrics and risk of severe hypoglycemia and diabetic ketoacidosis (DKA) in individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS We pooled individual-level data from 10 studies of type 1 diabetes. From a 14-day baseline period, we derived CGM metrics (time in range [TIR] 70–180 mg/dL, time above range [TAR], time below range [TBR], sensor mean glucose, SD, and percent coefficient of variation [%CV]) and CGM-defined hypo- and hyperglycemic episodes. We used Cox regression to evaluate associations with severe hypoglycemia and DKA, with and without adjustment for HbA1c. RESULTS Among 1,550 participants, 65 severe hypoglycemia and 163 DKA events occurred over a median follow-up of 16 weeks. Higher TBR <70 and <54 mg/dL, SD, %CV, and CGM-defined hypoglycemic episodes were associated with greater risk of severe hypoglycemia independent of HbA1c (e.g., hazard ratio [HR] 1.52 [1.29–1.79] per 1-SD higher TBR <70). Lower TIR and higher mean glucose, SD, %CV, TAR, and hyperglycemic episodes were associated with higher DKA risk; these associations were attenuated after HbA1c adjustment, but TIR, sensor mean glucose, and SD remained statistically and clinically significant (e.g., HR 0.76, 95% CI 0.60–0.97 per 1-SD higher TIR). CONCLUSIONS CGM hypoglycemic and glycemic variability metrics were associated with severe hypoglycemia risk independent of HbA1c, whereas TIR, mean glucose, and SD provided information for DKA risk beyond HbA1c. This supports the complementary value of CGM and HbA1c in risk assessment for severe hypoglycemia and DKA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
- Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD.
- Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
- Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University, Baltimore, MD.
ORCID-Profile: Jiahuan Helen He, Natalie Daya Malek, Justin B Echouffo-Tcheugui, Elizabeth Selvin
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
- Division of Diabetes, Endocrinology, and Metabolic Diseases
- National Heart, Lung, and Blood Institute
Zitieren
APA
He, J. H., Malek, N. D., Zeger, S. L., Echouffo-Tcheugui, J. B., Fang, M., & Selvin, E. (2026). Continuous Glucose Monitoring Metrics and Risks of Severe Hypoglycemia and Diabetic Ketoacidosis in Type 1 Diabetes: A Pooled Analysis. Diabetes Care. https://doi.org/10.2337/dc26-1042
Vancouver
He JH, Malek ND, Zeger SL, Echouffo-Tcheugui JB, Fang M, Selvin E. Continuous Glucose Monitoring Metrics and Risks of Severe Hypoglycemia and Diabetic Ketoacidosis in Type 1 Diabetes: A Pooled Analysis. Diabetes Care. 2026. doi:10.2337/dc26-1042
BibTeX
@article{He2026,
author = {He, Jiahuan Helen and Malek, Natalie Daya and Zeger, Scott L and Echouffo-Tcheugui, Justin B and Fang, Michael and Selvin, Elizabeth},
title = {Continuous Glucose Monitoring Metrics and Risks of Severe Hypoglycemia and Diabetic Ketoacidosis in Type 1 Diabetes: A Pooled Analysis},
journal = {Diabetes Care},
year = {2026},
doi = {10.2337/dc26-1042}
}
EUVIMED